Biospecimen Acquisition From Human Subjects
NCT: NCT00034216 ·
Status: RECRUITING ·
Phase: N/A
· Sponsor: National Cancer Institute (NCI)
· Started: 2002-07-16
Official Summary
This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate. This study does not involve treatment. Participants will have about 50 ml (3 tablespoonfuls) of blood drawn. Depending on their condition, patients may be invited to enroll in a clinical research study involving chemotherapy, radiotherapy, or surgery. Additional 40-ml blood samples may be drawn during the course of treatment.
Study Design
- Study Type: OBSERVATIONAL
- Enrollment: 1,750 participants
Primary Outcomes
- Undertake genetic analysis of both prokaryotic and eukaryotic samples for advanced mutational analysis. (ongoing)
- Correlate analysis results with clinical parameters such as demographics, toxicities, and treatment outcomes. (ongoing)
- Collection of tissue, urine, saliva, stool and blood components, which include serum, leukocytes, peripheral blood mononuclear cells (PBMC), and circulating tumor cells (cTC), of human subjects. (ongoing)
Trial Locations
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
More Prostate Cancer Trials
AI-generated analysis for educational purposes only. This is not medical advice. Discuss clinical trial participation with your doctor. Data sourced from ClinicalTrials.gov.